KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Discontinued OperationsCash from Discontinued OperationsCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities (2016 - 2023)

TherapeuticsMD filings provide 13 years of Cash from Financing Activities readings, the most recent being $2.0 million for Q4 2023.

  • On a quarterly basis, Cash from Financing Activities rose 101.79% to $2.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$108.2 million, a 54.0% increase, with the full-year FY2023 number at $3.2 million, up 101.34% from a year prior.
  • Cash from Financing Activities hit $2.0 million in Q4 2023 for TherapeuticsMD, up from -$1000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $111.7 million in Q2 2019 to a low of -$120.0 million in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was $890500.0 (2021), compared with a mean of $9.2 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 48669.82% in 2020 and later plummeted 28137.38% in 2022.
  • TherapeuticsMD's Cash from Financing Activities stood at $77.0 million in 2019, then tumbled by 58.84% to $31.7 million in 2020, then plummeted by 95.73% to $1.4 million in 2021, then crashed by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
  • The last three reported values for Cash from Financing Activities were $2.0 million (Q4 2023), -$1000.0 (Q3 2023), and -$111.9 million (Q4 2022) per Business Quant data.